Blood plasma transfusions with high concentrations of COVID-19 antibodies reduced deaths among some virus patients, according to a new study by Mayo Clinic researchers, which gives credibility to one of the few known treatments for the disease.
“Early administration of high-titer convalescent plasma against SARS-CoV-2 to mildly infected older adults reduced the development of Covid-19,” the researchers concluded.
The study was published in the New England Journal of Medicine on Wednesday, accompanied by an editorial on how the treatment works, entitled “(A Little) Clarity on Convalescent Plasma for Covid-19.”
“I think it is necessary for the medical community to continue to innovate and test treatments for treatment. Realistically, we are months away from getting a significant number of people vaccinated, ”said Dr. R. Scott Wright, Coordinator of the Mayo Clinics COVID-1
Patients who received antibody-rich plasma during the first three days of treatment saw better results, but the treatment was less effective in those who were treated longer and had to be placed in ventilators, researchers found.
“Patients who were on ventilator saw no benefit,” said Dr. Wright to the Star Tribune. “It was too late.”
The study reviewed 3,082 patients and found a 25% lower risk of death in patients receiving antibody-rich plasma.